Antonio Manuel Gutiérrez Garcia-rekin lankidetzan egindako argitalpenak (22)

2020

  1. Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era

    European Journal of Haematology, Vol. 104, Núm. 5, pp. 400-408

  2. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

    British Journal of Haematology, Vol. 188, Núm. 6, pp. 888-897

2018

  1. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm

    British Journal of Haematology, Vol. 182, Núm. 4, pp. 534-541

2017

  1. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI

    British Journal of Haematology, Vol. 176, Núm. 6, pp. 918-928

2014

  1. Gemcitabine and oxaliplatinum: An effective regimen in patients with refractory and relapsing Hodgkin lymphoma

    OncoTargets and Therapy, Vol. 7, pp. 2093-2100

2012

  1. Expression of COX-2 on reed-sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD

    Blood, Vol. 119, Núm. 25, pp. 6072-6079

2011

  1. Diffuse large B-cell lymphoma in the older

    Critical Reviews in Oncology/Hematology, Vol. 78, Núm. 1, pp. 59-72

2010

  1. Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: Potential role of a new sex- and age-adjusted reference value

    International Journal of Laboratory Hematology, Vol. 32, Núm. 6 PART 2, pp. 582-589

2009

  1. Frontline autologous stem cell transplantation for peripheral T-cell lymphoma

    Expert Review of Hematology

2008

  1. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: A phase II study

    European Journal of Haematology, Vol. 80, Núm. 2, pp. 127-132

  2. Hematopoietic SCT for peripheral T-cell lymphoma

    Bone Marrow Transplantation, Vol. 42, Núm. 12, pp. 773-781

  3. Pharmacokinetic properties of rituximab

    Reviews on Recent Clinical Trials, Vol. 3, Núm. 1, pp. 22-30

  4. Primary mediastinal large cell lymphoma (PMBL): Frontline treatment with autologous stem celltransplantation (ASCT). The GEL-TAMO experience

    Hematological Oncology, Vol. 26, Núm. 3, pp. 171-178

  5. Value of frontline autologous stem-cell transplantation in peripheral T-cell lymphoma

    Annals of Oncology

2007

  1. New treatment concepts in diffuse large B-cell lymphomas (DLBL): Chemotherapy and biological therapy

    Reviews on Recent Clinical Trials, Vol. 2, Núm. 2, pp. 149-162

  2. Tho adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma

    Haematologica, Vol. 92, Núm. 8, pp. 1067-1074

2006

  1. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma

    Leukemia and Lymphoma, Vol. 47, Núm. 1, pp. 111-115

2004

  1. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience

    Annals of Oncology, Vol. 15, Núm. 10, pp. 1504-1509

  2. Gemcitabine and oxaliplatinum: An effective regimen in a patient with progressive refractory mantle cell lymphoma

    Leukemia and Lymphoma, Vol. 45, Núm. 6, pp. 1289-1291

  3. Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma [2]

    European Journal of Haematology